Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has been assigned an average rating of “Hold” from the twenty analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation and five have assigned a buy recommendation to the company. […]